News - Anti-Arthritics/Rheumatics, Asia-Pacific

Filter

Popular Filters

Roche and Chugai’s SC RoActemra improves RA long term

Roche and Chugai’s SC RoActemra improves RA long term

28-10-2013

Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have announced that their RoActemra…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalPharmaceuticalResearchRoActemraRoche

Mitsubishi Tanabe succeeds in arbitration

11-08-2013

Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) says it has been awarded $117 million in an…

Anti-Arthritics/RheumaticsAsia-PacificJanssen BiotechJohnson & JohnsonLicensingMitsubishi TanabePharmaceuticalPricingRemicade

Chugai gains Japanese approval for Perjeta and Bonviva

28-06-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained…

Anti-Arthritics/RheumaticsAsia-PacificBonvivaChugai PharmaceuticalOncologyPerjetaPharmaceuticalRegulationRoche

Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China

14-06-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) and China-based Simcere Pharmaceutical (NYSE: SCR) have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyBristol-Myers SquibbLicensingOrenciaPharmaceuticalSimcere Pharmaceutical

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Proposal to list Roche's Neulastim and Actemra in New Zealand

24-05-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announce the approval of a proposal to list…

ActemraAnti-Arthritics/RheumaticsAsia-PacificNeulastimOncologyPharmaceuticalPricingRegulationRoche

Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar

17-04-2013

USA-based generic drugmaker Mylan (Nasdaq: MYL) says that it has delivered, through its South African-based…

AmgenAnti-Arthritics/RheumaticsAnti-viralsAsia-PacificBiotechnologyCiplaEnbrelEtaceptGenericsMarkets & MarketingMylan LaboratoriesPfizerRest of the World

New Zealand considers listing of Neulastim and Actemra

12-04-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list pegfilgrastim…

ActemraAnti-Arthritics/RheumaticsAsia-PacificBiotechnologyNeulastimOncologyPharmaceuticalPricingRegulationRoche

Regulatory briefs on Bayer's Stivarga, Boehringer/Lilly's empagliflozin and Pfizer's Xeljanz

26-03-2013

Drug regulator Health Canada has approved German drug major Bayer's Stivarga (regorafenib tablets), indicated…

Anti-Arthritics/RheumaticsAsia-PacificBayerBiotechnologyBoehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaOncologyPfizerPharmaceuticalRegulationStivargaXeljanz

Eli Lilly and Chugai to stop co-marketing of Evista in Japan

05-11-2012

The Japanese subsidiary of US drug major Eli Lilly (NYSE: LLY) and Roche's (ROG: SIX) majority-owned…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalEli LillyEvistaLicensingMarkets & MarketingPharmaceutical

AstraZeneca partners with WuXi AppTec to speed novel biologic to Chinese market

11-09-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has formed a joint venture with China's WuXi AppTec to…

Anti-Arthritics/RheumaticsAsia-PacificAstraZenecaBiotechnologyImmunologicalsInflammatory diseasesMEDI5117MedImmuneMergers & AcquisitionsPharmaceuticalResearchWuXi Apptec

New Zealand's PHARMAC agrees pricing deal with Sanofi for Arava

04-09-2012

New Zealand's national pharmaceuticals funding agency, PHARMAC, has announced changes to the listings…

Anti-Arthritics/RheumaticsAravaAsia-PacificLeflunomidePharmaceuticalPricingSanofi

Eisai and Toyama's iguratimod, and Astellas' Gonax OKed in Japan

03-07-2012

Japanese drug major Eisai (TYO: 4523) and Toyama Chemical have received approval from Japan's Ministry…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmaCareramdegarelixEisaiFerring PharmaceuticalsGonaxiguratimodKolbetOncologyPharmaceuticalRegulationToyama

Kyowa Hakko sets up biosimilars joint venture with Fujifilm

29-03-2012

Japanese digital camera and medical equipment conglomerate Fujifilm and drugmaker Kyowa Hakko Kirin have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyFujifilm Kyowa Kirin BiologicsGenericsHumiraKyowa Hakko KirinMergers & AcquisitionsResearch

Daiichi Sankyo files denosumab in Japan for osteoporosis

26-03-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) revealed on Friday that it has filed for approval in Japan…

AmgenAnti-Arthritics/RheumaticsAsia-PacificDaiichi SankyodenosumabPharmaceuticalRegulation

UCB links with Astellas for Cimzia in Japan

02-02-2012

Following the recent discontinuation of a commercialization accord for its rheumatoid arthritis drug…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmaCimziaLicensingPharmaceuticalUCB

Global osteoporosis market report sees strong showing in China

01-02-2012

The global market for drugs to treat osteoporosis was estimated to be worth $7.3 billion in 2010 and…

AmgenAnti-Arthritics/RheumaticsAsia-PacificGlobalMarkets & MarketingPharmaceuticalXgeva

Novartis gains NIH listing in Japan for Ilaris

23-11-2011

Swiss drug major Novartis’ (NOVN: VX) Ilaris (canakinumab), a treatment for cryopyrin-associated…

Anti-Arthritics/RheumaticsAsia-PacificIlarisNovartisPharmaceuticalPricingRare diseases

Bristol-Myers gets more rights to Ono antibody in exchange for Japan co-rights to Orencia

22-09-2011

US drug major Bristol-Myers Squibb (NYSE:BMY) says it has agreed with Japan’s Ono Pharmaceutical…

Anti-Arthritics/RheumaticsAsia-PacificBristol-Myers SquibbLicensingMarkets & MarketingOncologyOno PharmaceuticalOrenciaPharmaceutical

Teijin and Astellas expand collaboration on gout drug febuxostat

12-08-2011

Japanese drugmakers Teijin Pharma (TYO: 3401 and Astellas Pharma (TKO:4503) have entered into an exclusive…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmafebuxostatLicensingPharmaceuticalTeijin

Back to top